Introduction
The small ubiquitin-like modifier (SUMO) proteins regulate a diverse array of cellular functions, including mitosis, gene transcription, DNA repair, nucleocytoplasmic transport and subnuclear targeting (Verger et al., 2003; Seeler and Dejean, 2003; Muller et al., 2004) . There are three known functional SUMO isoforms (SUMO1, SUMO2 and SUMO3), which, through a wellestablished series of reactions, are conjugated to target proteins to exert post-translational modulation of protein function (reviewed by Johnson, 2004) . These effects are reversible through the action of SUMO-specific proteases. Recently, post-translational SUMOylation has been suggested to cause a depolarizing shift in the steady-state inactivation of the voltage-dependent K + (Kv) channel Kv1.5 (Benson et al., 2007) and to silence the K2P1 K + leak channel (Rajan et al., 2005) , although the latter finding is controversial (Feliciangeli et al., 2007) . Thus, SUMOylation of ion channels might represent a unique mechanism for the modulation of cellular electrical excitability.
Pancreatic islet β-cells secrete insulin in response to glucosestimulated electrical activity (Rorsman, 1997) . Kv2.1 is the major Kv channel responsible for action potential repolarization in these cells (MacDonald et al., 2001; MacDonald et al., 2002; Yan et al., 2004; Herrington et al., 2006; Jacobson et al., 2007) . The human Kv2.1 sequence contains three to six potential cytoplasmic consensus SUMOylation motifs. We have therefore examined the ability of SUMOylation to regulate the cloned human Kv2.1 channel and native Kv currents in insulinoma cells and primary human β-cells.
We find that expression or infusion of SUMO1 inhibits both cloned Kv2.1 and native Kv currents. This can be reversed by the SUMO protease SENP1. SUMOylation is associated with both an acceleration of time-dependent inactivation and delayed recovery from inactivation. Finally, we show that SUMOylation modulates the excitability of insulin-secreting cells in a manner consistent with the observed Kv current inhibition. Thus, SUMOylation is able to regulate native Kv currents and modulate β-cell excitability, and this might represent an important mechanism regulating insulin secretion.
Results and Discussion

SUMOylation inhibits Kv2.1 current
We coexpressed human Kv2.1 in HEK 293 cells together with a human SUMO1-YFP construct, and either the SUMO conjugating enzyme Ubc9 or the SUMO protease SENP1. SUMO1-YFP can effectively conjugate with its targets (Harder et al., 2004) , and when coexpressed with Kv2.1 is co-immunoprecipitated with an antiKv2.1 antibody (Fig. 1A) . The anti-GFP-positive signal was present at a range of molecular weights, suggesting that several SUMOylated proteins are pulled-down with the channel. We also consistently detected a high molecular mass band (>250 kDa) in the immunoprecipitate that is positive for both the channel and SUMO1-YFP (yellow in the overlay, Fig. 1 ), which could result from multi-SUMOylation of the channel or from association of the channel with an SDS-resistant protein complex. However, it seems clear that, as suggested previously (Benson et al., 2007) , only a minority (<1%) of channel proteins might be directly SUMOylated. Nonetheless, we find that SUMO1-YFP is co-immunoprecipitated with the Kv2.1 channel. Furthermore, this interaction is enhanced by coexpression of Ubc9 and lost upon coexpression of SENP1 (Fig. 1A) .
As SUMOylation of either Kv2.1 or its binding partners might regulate the channel, we examined the effect of SUMO1-YFP on (Fig. 1B,C ). These effects were probably not due to altered channel expression because whole-cell Kv2.1 protein levels did not change in concert with channel inhibition. Furthermore, acute infusion of recombinant human SUMO1 peptide (5 μM), alone or with recombinant Ubc9 (10 μg/ml), through the patch pipette, also inhibited Kv2.1 current (80% and 92% inhibition, n=14 and 13, respectively, P<0.001) (Fig. 1D ). Kv2.1 is the major Kv channel in insulin secreting β-cells where it regulates action potential repolarization and insulin secretion (MacDonald et al., 2001; Yan et al., 2004; Jacobson et al., 2007) . We detected the expression of mRNA encoding SUMO1 and SUMO3, but not SUMO2, by RT-PCR of INS-1 832/13 cells, mouse islet and human islet cDNA (not shown). Expression of the SUMO1-YFP in INS-1 832/13 cells, a common insulinoma model (Hohmeier and Newgard, 2004) , inhibited endogenous Kv currents by 33% (n=27, P<0.05). Coexpression of Ubc9 had little additional inhibitory effect in the INS-1 832/13 cells, although this could perhaps be owing to differing levels of endogenous SUMOconjugating enzymes in the two models. Nonetheless, and similar to our observations in HEK 293 cells overexpressing Kv2.1, the inhibitory effect was prevented by coexpression of SENP1 (n=12) (Fig. 1E,F) . The overall inhibitory effect of SUMO1-YFP was less than observed in HEK 293 cells, and this is probably because of the mixed nature of the native currents in INS-1 cells which also express several additional Kv isoforms (Su et al., 2001 ).
SUMOylation regulates native Kv currents in human β-cells
We were interested in whether SUMO1 can regulate Kv currents in primary human β-cells because as much as 60% of these are contributed by Kv2.1 (Herrington et al., 2005) . Expression of the SUMO1-YFP in primary human β-cells from three healthy donors inhibited native Kv currents ( Fig. 2A-D) . Overall, combining results from the donors, SUMO1-YFP resulted in a 49% (n=27, P<0.05) reduction in native Kv current compared to controls expressing EGFP alone (Fig. 2E ). Coexpression of SENP1 was able to largely prevent the inhibition of native Kv current by SUMO1-YFP (n=7) (Fig. 2E) , demonstrating the importance of SUMO conjugation for the inhibitory effect. Furthermore, the direct infusion of recombinant human SUMO1 peptide (5 μM) or SUMO1 with Ubc9 (10 μg/ml) in β-cells from two additional donors inhibited native Kv currents by 41% and 58% respectively (n=16 and 9, P<0.05) (Fig. 2F,G) .
SUMOylation regulates Kv2.1 inactivation
In response to a 10-second depolarization, cloned Kv2.1 inactivated slowly [time constant (τ)=11.7±1.4 seconds, n=16] (Fig. 3A,B) . Coexpression of SUMO1-YFP quickened the time-dependent inactivation of Kv2.1 (τ=8.2±1.2 seconds, n=19, P<0.05). This effect was enhanced by the additional presence of Ubc9 (τ=5.3±0.7 seconds, n=12, P<0.01) compared with SUMO1 alone (P<0.05), and was reversed by SENP1 (τ=9.6±1.4 seconds, n=14) (Fig. 3A,B) . Similar results were obtained from human β-cells, where inactivation of Kv current was fit to an exponential decay with both fast (τ 1 ) and slow (τ 2 ) time constants (MacDonald et al., 2003; Herrington et al., 2005) . In human β-cells, τ 1 was 0.6±0.2 seconds (n=10) and this was significantly decreased by coexpression of SUMO1-YFP and Ubc9 (0.2±0.1 seconds, n=13, P<0.05). Similarly, τ 2 in the human β-cells, most probably represents the contribution Journal of Cell Science 122 (6) of native Kv2.1 (Braun et al., 2008) , and was reduced from 3.5±0.6 seconds (n=10) to 2.1±0.2 seconds (n=13, P<0.05) by expression of SUMO1-YFP together with Ubc9.
Additionally, we found that the recovery of Kv2.1 from inactivation is impaired by SUMOylation (Fig. 3C-E) . The recovery from inactivation at 65.5 seconds (Fig. 3D) In contrast to the recent study examining the effect of SUMOylation on cloned Kv1.5 current (Benson et al., 2007) , we find that SUMOylation had no effect on the voltage-dependence of steady-state inactivation of either cloned Kv2.1 (Fig. 3F) or native INS-1 832/13 or human β-cell Kv currents. Half-inactivation of the cloned Kv2.1, INS-1 Kv currents and human β-cell Kv currents was -25.3±0.3 (n=14), -33.8±0.3 (n=12) and -39.1±1.3 mV (n=15), respectively, and these were unchanged by expression of SUMO1-YFP alone or together with Ubc9 or SENP1. Thus, the exact mechanism for channel regulation might differ somewhat between the Kv1.5 and 2.1 isoforms. Our present results suggest that SUMOylation inhibits Kv2.1 by quickening channel inactivation and slowing the recovery from this inactivation. The reduced current observed in the sequential depolarizations in Figs 1 and 2 probably results from cumulative channel inactivation and an associated failure to recover from this during the interpulse interval. This would have important consequences on repetitive action potential firing.
SUMOylation modifies β-cell excitability
We examined action potential generation in the INS-1 832/13 cells (Fig. 4A) . Action potentials were elicited in the whole-cell currentclamp mode by a 10 pA current injection (Fig. 4A) . In control cells, action potential firing occurred with a frequency of 15.7±3.2 Hz (n=16) and was significantly reduced by expression of SUMO1-YFP (to 6.5±2.2 Hz, n=12, P<0.05) (Fig. 4A,B) . Firing was almost completely ablated by coexpression of SUMO1-YFP and Ubc9 (2.0±1.4 Hz, n=7, P<0.01) (Fig. 4A,B) . Similar to effects on the cloned and native Kv currents, action potential firing was restored by the coexpression of the SENP1 (to 15.1±1.7 Hz, n=4).
Action potential half-width was increased by expression of SUMO1-YFP, from 7.7±1.3 mseconds (n=10) to 24.7±4.6 ms (n=6, P<0.001), and this was reversed by the coexpression of SENP1 (12.5±1.3 mseconds, n=4) (Fig. 4C) . This is consistent with the SUMOylation-dependent inhibition of Kv current and probably explains the observed effects on firing frequency. We also observed a reduced amplitude of the action potential peak upon expression of SUMO1-YFP, from 7.8±2.1 mV (n=10) to -2.4±3.8 mV (n=6, P<0.05), which was also rescued by coexpression of SENP1 (4.9±3.1 mV, n=4). This latter finding is somewhat surprising and probably not explained by inhibition of Kv current. It seems possible that inhibition of voltage-dependent Ca 2+ or Na + channels might underlie the changes in action potential peak amplitude, but this remains unexplored. Nonetheless, the present results demonstrate that channel SUMOylation can exert strong regulatory effects on β-cell excitability that are consistent with Kv current inhibition.
Conclusions
Reversible protein SUMOylation has a well-recognized role in several cellular functions (Verger et al., 2003; Seeler and Dejean, 2003; Muller et al., 2004) . Although a role in the acute regulation of cellular excitability was recently suggested (Rajan et al., 2005; Benson et al., 2007) , it remains controversial as to whether direct SUMOylation can modulate ion-channel function (Feliciangeli et al., 2007) . In the present work we have demonstrated that SUMOylation is indeed able to regulate Kv2.1 and native Kv currents of insulinoma and human β-cells. This occurs as a result of distinct effects on the rate of, and recovery from, channel inactivation. Although it remains unclear as to whether this results from SUMOylation of the channel or of a channel binding partner, we now show that SUMOylation processes can exert a strong modulatory effect on cellular excitability and action potential firing that is consistent with the inhibition of Kv2.1. Finally, the present work suggests that SUMOylation processes might represent a novel and important mechanism for regulating pancreatic β-cell insulin secretion.
Materials and Methods
Recombinant constructs, cells and cell culture
The human SUMO1-YFP (Harder et al., 2004) was in the pEYFP-C3 vector (Clontech, Palo Alto, CA). The human SUMO1 (untagged), Ubc9 and SENP1 constructs in the pCMV6-XL4 vector were from Origene Technologies (Rockville, MD). The human Kv2.1 construct (MacDonald et al., 2002) was in the pcDNA3.1+ vector (Invitrogen Canada, Burlington, Canada) and was originally from Rolf H. Joho (University of Texas Southwestern Medical Center, Dallas, TX). The pIRES-EGFP vector (Clontech) was used for control transfections. Recombinant human SUMO1 and Ubc9 peptides were from GeneTex (San Antonio, TX).
HEK 293 cells were cultured in DMEM with 10% (v/v) fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C and 5% CO 2 . INS-1 832/13 cells (a kind gift from Christopher B. Newgard, Duke University, NC) were cultured in RPMI 1640 medium containing 11.1 mM glucose and supplemented with 10% fetal bovine serum, 10 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 μM β-mercaptoethanol, 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C and 5% CO 2 . Human islets from five healthy donors were provided by James Shapiro (University of Alberta, Alberta, Canada) and the ABCC Human Islet Distribution Program at the University of Alberta. Islets were dispersed to single cells by shaking in Ca 2+ -free buffer. Primary β-cells were positively identified following patch-clamp by immunostaining for insulin. Cell lines and primary cells were transfected using Lipofectamine 2000 (Invitrogen Canada). All experiments on human cells were approved by the Human Research Ethics Board at the University of Alberta.
Western blotting and immunoprecipitation
Cells were homogenized in lysis buffer, which contained (in mM): 20 HEPES (pH 7.4 with KOH), 100 NaCl, 40 KCl, 1 EDTA, 20 NEM, 10 NaF, and 1 Na 3 VO 4 with 10% glycerol, 1% Triton X-100, and protease inhibitor cocktail (1:100 dilution, SigmaAldrich Canada, Oakville, Canada). Cell lysates were subjected to 1 hour pre-clearing with protein G-Sepharose (Zymed Laboratories, San Francisco, CA) followed by incubation with anti-Kv2.1 antibody (Alomone Labs, Jerusalem, Israel) overnight at Journal of Cell Science 122 (6) 4°C and with protein G-Sepharose for 4 hours at 4°C. The immunoprecipitated material was analyzed by immunoblotting with anti-Kv2.1 (1:500) and anti-GFP (1:500, Clontech, Mountain View, CA). Anti-mouse IRDye 800CW and anti-rabbit IRDye 680 secondary antibodies were used at 1:5000. Images were obtained using an Odyssey infrared imaging system (LI-COR, Lincoln, NE).
Electrophysiology
Whole-cell patch-clamp was performed with an EPC10 patch-clamp amplifier controlled with PatchMaster software (HEKA Electronik, Lambrecht, Germany). Patch pipettes were pulled from thin-walled borosilicate glass tubes and had a resistance between 3 and 5 MΩ when fire-polished, coated with Sylgard and filled with intracellular solution. The intracellular solution was composed of (in mM): 140 KCl, 1 CaCl 2 , 1 MgCl 2 , 10 HEPES, 10 EGTA and 3 ATP-Mg (pH 7.3 with KOH). The bath solution was composed of (in mM): 135 NaCl, 5.4 KCl, 1 CaCl 2 , 1.2 MgCl 2 , 10 HEPES and 5 glucose (pH 7.3 with NaOH). Experiments on cloned channels were at room temperature and experiments on native currents were at 32-35°C.
Current-voltage relationships were generated by sequential 500-msecond depolarizations from a holding potential of -70 mV with a 6-second intersweep interval. Time-dependent inactivation time constants were determined during a 10-second depolarization to +30 mV. Recovery from inactivation was determined by varying the recovery time (at -70 mV) between sequential 5-second and 500-msecond depolarizations to +30 mV. Steady-state inactivation was determined by a 500-msecond depolarization to +30 mV from holding potentials between -100 and +30 mV. Action potential firing was elicited in the whole-cell current-clamp mode by injection of a 10 pA current. Data was analyzed using FitMaster (HEKA Electronik) and SigmaPlot 10 (Systat Software, Point Richmond, CA) and compared by multiple ANOVA and Student's t-test. Data is expressed as mean ± s.e.m. and P-values of less than 0.05 were considered significant.
